Capsida Biotherapeutics

Capsida Biotherapeutics, based in Newbury Park, CA, is a fully integrated next-generation gene therapy company focused on developing potentially disease-modifying and curative treatments for both rare and common diseases. With a proprietary approach to engineered capsids, Capsida aims to deliver high-quality, targeted therapies that address significant unmet medical needs across all ages.

Founded in 2019, Capsida leverages advanced technology and a streamlined manufacturing process to expedite the development of its gene therapies, which are designed for intravenous administration. The company is actively progressing multiple programs in central nervous system disorders, including STXBP1 developmental and epileptic encephalopathy, as well as Parkinson's disease linked to GBA mutations, with clinical development expected to begin in the first half of 2025.

Generated from the website